Eagle Pharmaceuticals (EGRX) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mizuho Securities Remains Bullish on Eagle Pharmaceuticals (EGRX) Despite Weak 4Q; Investors Focus on Bendeka Opportunity
February 26, 2016 7:04 AM ESTMizuho Securities maintained a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $81.00 (from $112.00), following the company's 4Q earnings report. EGRX reported 4Q revenues of $18.2M and EPS of $0.07, missing the consensus estimates of $20.8M and $0.30. The most... More
